Month: July 2020

Selva Therapeutics Announces $3 Million Series A Financing to Advance a Novel Broad Spectrum Antiviral for Infectious Diseases, Including COVID-19


Excerpt from the Press Release: “SAN DIEGO–(BUSINESS WIRE)–Selva Therapeutics, Inc. announced today that the company has raised $3 million in a Series A financing round from private investors. The proceeds of the financing will be used to rapidly advance SLV213 into clinical trials as a leading oral drug candidate for the treatment of COVID-19, the…

Read More

PerkinElmer Releases New Dried Blood Spot Based COVID-19 Serology Test


Excerpt from the Press Release: “WALTHAM, Mass.–(BUSINESS WIRE)–PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced the launch of a dry blood spot (DBS) based test for SARS-CoV-2 IgG using its GSP®/DELFIA® platform, enabling processing of up to 5,000 samples per day. The finger-prick sample collection device allows for…

Read More

Two COVID-19 Clinical Trials Seek to Enroll Pregnant Women


From The Scientist comes this exciting new development in clinical research into COVID-19: “Upon seeing pregnant women sick with COVID-19 at a University of Pennsylvania hospital, researchers there wrote trial protocols for blood transfusions to treat the disease that include expecting mothers. As a translational infectious disease researcher at the University of Pennsylvania Perelman School…

Read More

Sonnet Biotherapeutics Announces Positive Preclinical Results from an Initial Efficacy Study Exploring the Combination of Granulocyte-Macrophage Colony-Stimulating Factor with Interleukins 18 and 12


Excerpt from the Press Release: “PRINCETON, NJ / ACCESSWIRE / July 20, 2020 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing innovative targeted biologic drugs with enhanced mono or bispecific mechanisms, announced today that it has completed initial preclinical proof-of-concept work with both GMcSF and IL-18 and with GMcSF and IL-12 in a…

Read More

Innovation Pharmaceuticals’ Brilacidin Inhibits Novel Coronavirus (COVID-19) by Almost 90% at the Lowest Concentration Tested to Date in a Human Lung Cell Line


Excerpt from the Press Release: “WAKEFIELD, MA – July 20, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, reports today receiving new data from ongoing laboratory testing being conducted at a U.S. Regional Biocontainment Laboratory (RBL). The data is helping to inform the planned Phase 2 clinical trial of Brilacidin…

Read More

Albireo Launches Expanded Access Program for Odevixibat for Patients in the U.S., Canada, Australia and Europe


Excerpt from the Press Release: “BOSTON, July 20, 2020 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the launch of an Expanded Access Program (EAP) for investigational lead product candidate odevixibat, a highly potent and selective inhibitor of the ileal bile…

Read More

ASCO & ACCC Join Forces to Increase Participation of Racial and Ethnic Minority Populations in Cancer Treatment Trials


Excerpt from the Press Release: “Alexandria, VA—The American Society of Clinical Oncology (ASCO) and Association of Community Cancer Centers (ACCC) today announced a new collaboration to foster participation in cancer treatment trials to more fully reflect the diversity of people at risk for or living with cancer. The joint ASCO-ACCC initiative is designed to identify…

Read More

‘Planning to vaccinate everyone in the US,’ Moderna outlines efforts to supply their Covid-19 vaccine as manufacturing ramps up ahead of PhIII


Excerpt from the article: “Twelve days from the planned start of their Phase III pivotal trial, the executive crew at Moderna has set up the manufacturing base needed to begin production of the first 500,000 doses of their Covid-19 vaccine with plans to feed it into a global supply chain. But the initial batches will…

Read More

Oncorus Initiates First-in-Human Phase 1 Study of ONCR-177 for the Treatment of Adult Subjects with Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors


Excerpt from the Press Release “CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oncorus, Inc., a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that it has initiated a Phase 1 study of its lead product candidate, ONCR-177, an intratumorally administered oncolytic Herpes Simplex Virus (oHSV) viral immunotherapy being developed for multiple solid tumor…

Read More

Heron Therapeutics Announces Initiation of Phase 2 Clinical Study of CINVANTI® for the Treatment of COVID-19


Excerpt from the Press Release: “SAN DIEGO, July 16, 2020 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the initiation of the GUARDS-1 Study, a Phase 2 clinical study…

Read More